Friday, March 8, 2013
Paper of the Week: Mechanistic dissection of a heart disease risk variant
ADAMTS7 encodes a metalloprotease which cleaves protein in order to activate them. One of its substrates is COMP, known as thrombospondin-5, which is known to be made by vascular smooth muscle cells (VSMC) and inhibit their migration. The authors noted that ADAMTS7 accumulated in smooth muscle cells in both carotid and coronary atherosclerotic plaques. The relevant genetic variant here is rs3825807, calling for a nonsynonymous A to G, leading to a substitution at amino acid 214, Ser to Pro, in the prodomain of the ADAMTS7 protease. VSMCs harboring the G/G genotype for rs3825807 had attenuated migratory ability, while conditioned media of VSMCs of the G/G genotype contained less of the cleaved form of COMP.
The authors write that "the results of our study indicate that rs3825807 has an effect on ADAMTS7 maturation, thrombospondin-5 cleavage, and VSMC migration, with the variant associated with protection from atherosclerosis and CAD (coronary artery disease) rendering a reduction in ADAMTS7 function." I find this a noteworthy study because it takes a GWAS hit for CAD risk and informs us as to how that allele can lead to plaque formation and atherosclerosis.
Thursday, March 10, 2011
Genetics of coronary heart disease
Last week, Nature Genetics published three letters reporting results from genome-wide association studies (GWAS) for coronary heart disease (CAD). The studies reported a number of markers that reached the threshold of statistical significance for association to CAD with concomitant association to traditional biomarkers of disease risk, such as elevated LDL-cholesterol (LDL-C), elevated total cholesterol, decreased HDL-cholesterol (HDL-C), hypertension, obesity (as measured by elevated body mass index), or type 2 diabetes. However, the two larger and more highly powered GWAS (C4D Genetics Consortium, Schunkert, et al.) also identified CAD-associated variants that are not associated with traditional biomarkers. The third study is of interest because it examines CAD in Chinese populations, but beginning with a discovery set of 130 cases and 130 controls leaves it a bit under-powered. They report a unique association between a SNP in C6orf105 and CAD, which is not found in European or south Asian populations. Curiously, this gene has also been implicated in non-syndromic oral cleft.
There are many sources of CAD. Blood lipids are most commonly thought of as the prime source, but blood pressure in the form of hypertension is also a source. Traditional biomarkers such as LDL-C, HDL-C, triglycerides, and hypertension have been used almost as the sole surrogates for measuring the devolvement and progression of CAD over the course of some 50 years. Meta-analyses of GWAS based on over 100,000 subjects (22,233 cases and 64,762 controls from 14 GWAS) thus far have identified 23 genetic variants associating with CAD. The eye-opening aspect to this is these variants account for about 10% of CAD cases with the shocking observation that 17 of 23 confirmed loci appear to have no association with traditional markers. This observation then suggests two possible explanations.
One possibility is when we assume that the remainder of the CAD cases (90%) contribute to risk associated with traditional markers, such genetic factors cannot be detected based on current GWAS methodology. This is likely to be true because of to the effect sizes of these variants are too small, or their effects are camouflaged by gene-gene (GxG) and gene-environment (GxE) interactions or by epigenetic mechanisms.
This second possibility rests on the fundamental premise that all markers associating with CAD have more or less equal chance to be detected. It then follows that a majority of genetic factors that contribute to CAD has nothing to do with traditional markers. If this is indeed the case, it opens a new avenue to identify the new mechanism(s) and new biomarkers that lead to CAD. In fact, this possibility is supported by many observations. For example, 50% of those individuals who have CAD have low LDL-C (Braunwald & Shattuck; Ridker).
These genes – for example, ADAMTS7, PDGFD, ABO and PPAP2B – point to new mechanisms. While GxG, GxE and epigenetic interactions remain as viable contributors to CAD risk, the path to better understanding of the other component(s) to CAD risk will likely transit through metabolic profiling to identify the compounds that distinguish elevated from nominal risk. Furthermore, research will need to be conducted in model organisms based on these newly discovered genes, perhaps in pig as this is a good model for heart function and disease in human.
Friday, May 21, 2010
Lipoprotein-associated phospholipase A2 and heart disease-risk
The compound in question is lipoprotein-associated phospholipase A2 (Lp-PLA2). This is also known as PLA2G7. While this blood factor is also associated with risk of heart disease in Whites, that association is not always accurate.
A colleague of mine offers that this result is interesting. Publication in JCEM rather than a cardiology journal may be related to the relatively small samples - "336 Caucasians and 224 African-Americans who were about to undergo diagnostic coronary arteriography."
With respect to the differences, obesity prevalence is 51% greater in African Americans than Whites, which could be relevant to inflammation. Alternatively, coronary disease in African Americans may be more advanced than in Whites at the point at which arteriography is performed.
I agree - especially in terms of disparities in health care among groups of ethnic minority in the USA.
----------
Reference
Enkhmaa B, Anuurad E, Zhang W, Pearson TA, Berglund L. (2010) Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population. Atherosclerosis. in press.
Wednesday, January 6, 2010
Positive selection and risk of heart disease
The implication that genetic variants under positive selection have a role in human disease is profound. These polymorphisms sense the local environment - diet, sunlight, sleep, exercise, alochol and tobacco use, exposure to pathogen, etc. - and participate in an allele-specific response of the cell, tissue, organism to that stimulus if you will. Thus, modification of one's lifestyle choices based on genotypes may be a viable choice to maintain a heathly condition. Before that, though, it will be necessary to define the effects of many, many more genetic polymorphisms, both SNPs and copy number variants (CNVs). To date we've compiled over 650 such examples where the SNP-phenotype association is modified by environment/diet. These pertain mostly to blood lipids such as LDL-cholesterol, HDL-cholesterol, triglycerides and total cholesterol. CNVs are generally under-studied in such work.
A summary of the review article is here:
Purpose of review: Obesity, cardiovascular disease and unhealthy levels of blood lipids known as dyslipidemia are complex and arise from both genetic and environmental factors as well as their interrelationships. Both large-scale genetic experiments and approaches focused on a single gene have resulted in identification of many genetic variants that are related to lipid and obesity measures. However, these variants still account for only a small fraction of the observed differences in these measures.
Recent findings: That many such genetic associations to obesity and lipid measures involve genetic variants under natural selection and that those variants are sensitive to environmental cues together suggest prominent roles for both natural selection and the interaction with the environment. Genetic variants under natural selection which interact with the environment modulate susceptibility to disease but the level to which those variants contribute to dyslipidemia and obesity and how environmental factors, especially diet, alter the genetic relationship is not yet completely described.
Summary: It is evident that genetic variants under natural selection make important contributions to obesity and heart disease risk. Advances in resequencing the entire human genome will enable accurate identification of genetic variants under positive selection. This will add power to large-scale genetic studies and allow for characterization of the relationship between natural selection and the obese and dyslipidemic conditions.